Fortral

Quick links to important sections

Fortral

Method of action: Analgesic, Opioid

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fortral

Property Description
Active ingredient Pentazocine (Hydrochloride or Lactate)
Form Tablet, Solution for injection
Pharmacological class Opioid analgesic (Mixed agonist-antagonist)
General use Relief of moderate to severe pain
Origin Synthetic (Benzomorphan derivative)

What is Fortral and How is it Classified?

Fortral is the brand name for the medicine whose active ingredient is Pentazocine, which is classified as a synthetic opioid analgesic. It is not a natural opiate but a manufactured compound belonging to the benzomorphan series. The medication's specific pharmacological designation is a mixed agonist-antagonist analgesic, a key differentiating factor that means Pentazocine simultaneously stimulates and weakly blocks specific opioid receptors in the central nervous system. Its use is for managing pain in settings where an intermediate-acting opioid profile is desired.

Fortral's Composition and Available Forms

The core chemical component of Fortral is Pentazocine, typically supplied as the salt form Pentazocine Hydrochloride or Pentazocine Lactate. As a pharmaceutical preparation, it is offered in several official dosage forms, including solid tablets for oral use and an aqueous solution intended for parenteral delivery, such as intramuscular or intravenous injection. The inclusion of an oral tablet form provides versatility in administration compared to injectables. Many oral formulations are formulated as a combination product that integrates an opioid antagonist, such as Naloxone, alongside the Pentazocine, which impacts the drug's overall identity and intended use context.

What is the General Purpose of Pentazocine?

The general purpose of Pentazocine is centered on providing pain relief for patients experiencing moderate to severe pain, such as post-operative discomfort or pain related to acute injury. This medicine is used to manage painful conditions by altering the body's perception of pain. The medicine achieves this by acting directly on central neurological pathways, which is its fundamental benefit: alleviating the patient's discomfort by dampening the signals of suffering in a manner distinct from non-opioid medications.

Regulatory References

  1. NIH DailyMed Pentazocine
  2. MedlinePlus Drug Information on Pentazocine

What side effects are possible with Fortral?

Possible Side Effects and Safety Information

The official safety documentation for pentazocine (Fortral) strictly defines its risk profile by classifying adverse events and detailing specific safety constraints, as documented in regulatory sources such as the FDA and the SmPC. Adverse reactions are systematically grouped by affected body system and frequency.


Officially Documented Adverse Reactions

The most commonly reported adverse reactions are generally related to the Central Nervous System (CNS) and Gastrointestinal (GI) systems, and include nausea, vomiting, dizziness or lightheadedness, and euphoria. Other frequently documented effects across system-organ classes include sedation, headache, confusion, hypertension (elevated blood pressure), and sweating.

Serious Safety Constraints

Official labeling documents critical safety concerns, including life-threatening respiratory depression, which is noted to be greatest upon initiation of therapy or following a dose increase. Pentazocine carries a documented risk of physical dependence, abuse, and misuse, and its administration to individuals dependent on pure opioid agonists may precipitate opioid withdrawal symptoms. Rare, but serious, reactions such as anaphylaxis are also noted in regulatory texts.

Population-Specific Considerations

Safety statements are explicitly specified for certain groups. Caution is required in elderly patients and individuals with hepatic (liver) or renal (kidney) impairment, as they may be more sensitive to the drug’s effects. Prolonged maternal use during pregnancy can result in Neonatal Opioid Withdrawal Syndrome in the newborn. Use is also restricted in patients with severe respiratory depression or suspected gastrointestinal obstruction, such as paralytic ileus.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define an overdose of Fortral (Pentazocine) by specific, severe clinical and physiological manifestations. These presentations often involve profound Central Nervous System (CNS) depression, progressing from drowsiness and confusion to unresponsiveness or coma. The most serious documented manifestation is life-threatening respiratory distress, characterized by shallow or slow breathing that can lead to apnea (no breathing) and cyanosis.

Cardiovascular signs, including hypotension (low blood pressure) and heart rhythm disturbances, are also documented. In cases of overdose, seizures, hallucinations, and shock may occur. Regulatory guidance emphasizes that accidental ingestion of even one dose can result in a fatal overdose, particularly in children. Furthermore, concurrent use with other CNS depressants, such as alcohol or benzodiazepines, is explicitly stated to exacerbate the effects, potentially leading to profound sedation, respiratory arrest, and death.

Due to the documented severity of these outcomes, regulatory authorities mandate that immediate medical help must be sought for any suspected or known overdose. The specific management involves clinical procedures to maintain ventilation and circulation, and the administration of Naloxone, which is documented as the specific antagonist for reversing the associated respiratory depression, often requiring multiple doses.

Therapeutic Uses of Fortral

What Fortral Treats: Main Uses and Benefits

Fortral (Pentazocine) is an analgesic medication that is commonly used in situations where patients experience symptoms related to physical discomfort, relevant for easing pronounced pain, in contexts where additional symptomatic support is needed.

The medication may assist with managing symptom clusters that can become intense or disruptive, such as those associated with acute injury, postoperative recovery, or discomfort during labor. It is considered relevant for managing symptoms that interfere with daily comfort, particularly in scenarios where additional management of discomfort is required.

It is applied across domains where additional symptomatic support is needed, including acute pain episodes and for providing short-term symptomatic assistance in various clinical procedures. The medication supports the patient during difficult episodes by easing distress and contributes to easing the overall symptom load.


Quick Fact: Relief for Moderate to Severe Pain

Regulatory References

  1. U.S. National Library of Medicine DailyMed

Eligibility and Restrictions for Use

Official Population Eligibility for Fortral (Pentazocine)

Fortral (Pentazocine) eligibility is strictly defined by regulatory documents, outlining populations permitted for use and those for whom the medicine is contraindicated or requires caution.

Absolute Contraindications:

Category Non-Eligibility Criteria
Allergy/Reaction Known hypersensitivity to pentazocine or any formulation ingredient.
Respiratory Significant respiratory depression or severe bronchial asthma in an unmonitored setting.
Gastrointestinal Known or suspected gastrointestinal obstruction, including paralytic ileus.

Age and Conditional Use Restrictions:

Eligibility is generally established for adults requiring relief from moderate to severe pain. Use is not established for children younger than 1 year (injection) or under 12 years (some oral forms). Older adults may be more sensitive and should be approached with caution.

Specific restrictions apply to patients with impaired hepatic or renal function, requiring administration with caution. Additionally, the drug is not recommended immediately prior to labor, and prolonged use during pregnancy carries the risk of Neonatal Opioid Withdrawal Syndrome (NOWS). Caution is also warranted for patients with a history of drug dependence, head injury, or those in the acute phase of myocardial infarction, as stated in the prescribing information.

What should I know about interactions with other medicines?

Fortral (Pentazocine) has formally documented interaction patterns that establish mandatory co-administration restrictions, primarily due to pharmacodynamic and pharmacokinetic effects as noted in regulatory labeling.

Documented Pharmacodynamic Interactions

Co-administration with Central Nervous System (CNS) Depressants, including alcohol, results in additive pharmacologic effects, significantly increasing the risk of profound sedation and respiratory depression. The combination with Serotonergic Drugs (such as SSRIs and SNRIs) may result in the development of serotonin syndrome.

Co-use with other mixed agonist/antagonist or partial agonist opioids (e.g., Buprenorphine, Nalbuphine) is documented to potentially reduce the analgesic effect of Pentazocine and/or precipitate withdrawal symptoms.

Mandatory Regulatory Restrictions

Restriction Type Interacting Substance/Class Official Constraint
Contraindicated Timing Monoamine Oxidase Inhibitors (MAOIs) Must not be administered within the preceding 14 days due to risk of CNS excitation and hypertension.
Metabolic Clearance Tobacco (Smoking) Documented to enhance the metabolic clearance rate of Pentazocine, which may reduce clinical exposure.
Population Note Liver Impairment Decreased metabolism in these patients may lead to the accentuation of side effects, as noted in official prescribing information.

Interactions are also documented with certain supplements like Tryptophan and the herbal product St. John’s Wort.

Mechanism of Action

️ Pharmacodynamic Mechanism of Pentazocine

Fortral's active substance, pentazocine, acts on the central nervous system (CNS) as a mixed opioid agonist-antagonist, engaging multiple receptor types to modulate signal transmission. Its primary action involves full agonism at the kappa (kappa)-opioid receptors (KORs).

This KOR engagement modulates the release of key neurotransmitters, including Substance P and glutamate, within the spinal cord and brain. This pathway effect modifies signal transmission in neural circuits associated with nociception.

Concurrently, pentazocine interacts with the mu (mu)-opioid receptors (MORs) as a partial agonist or weak antagonist, affecting the downstream signaling consequences typically initiated by MOR agonism. The compound also engages the Sigma non-opioid intracellular receptor 1 (sigma1 receptor) as an agonist, a mechanism hypothesized to influence feedback regulation within specific neuronal pathways.

Dosage and Administration Information

Fortral, which contains the active ingredient pentazocine, is an opioid analgesic used for the management of moderate to severe pain. It is critical to take this medication exactly as prescribed by your healthcare provider to minimize the risk of dependence and misuse.

Administration Guidelines

Dosage Form Route of Administration General Dosing Instructions
Oral Tablet By mouth Typically taken every 3 to 4 hours as needed for pain. Do not exceed the maximum daily dose prescribed by your doctor.
Injection Intramuscular (IM), Intravenous (IV), or Subcutaneous (SC) Administered by a trained health professional, often in a hospital setting for severe pain. The route (IM is preferred for frequent injections) and dosage are individualized.

Do not attempt to dissolve and inject oral tablets as this can cause serious health complications, including severe tissue damage and death. The tablet formulation may contain an agent to discourage this misuse.

Important Precautions

  • Dosage Adjustment: Your dose will be tailored to the severity of your pain, your response to the medication, and your individual risk factors. Do not change the dose or frequency without consulting your doctor.
  • Discontinuation: If you have been taking Fortral regularly for an extended period, do not stop taking it suddenly. Abrupt discontinuation can lead to severe withdrawal symptoms. Your doctor will provide instructions for a gradual dose reduction (tapering).
  • Storage: Store the medication in its original, closed container at room temperature, secured away from heat and moisture. Keep it out of sight and reach of children and others in the home.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fortral (Pentazocine)


Evidence for Managing Acute Pain and Post-Operative Discomfort

Clinical evaluation of Fortral (Pentazocine) has frequently involved studies in acute pain settings, such as after surgery or during sudden, severe pain episodes. Researchers primarily used Randomized Controlled Trials (RCTs) and systematic reviews in this area. These trials examined patient-reported experiences and were used in research exploring patterns observed in symptoms over a short time. The outcomes monitored included the time to onset that studies observed and the measurement of symptom intensity, often measured using specific pain rating scales, primarily in adult populations.

Studies conducted during periods of increased symptom activity reported that the research highlights changes measured during the study period, particularly within the first day or two after administration. Findings describe patterns observed in the studies related to the change in pain scores and the duration of action that was studied relative to the specific comparators used.


Evidence for Non-Acute and Chronic Pain Contexts

Research examining the use of Fortral for pain outside of immediate hospital or surgical recovery, such as for general acute pain in the community setting or for chronic pain conditions, is less abundant and often consists of older data. Official regulatory and health technology assessments, which review the body of evidence, have indicated that certainty remains low regarding the research exploring the use of Pentazocine for long-term chronic pain conditions. Long-term data are limited regarding sustained outcomes related to physical discomfort. Authoritative scientific reviews have often determined that the available literature is insufficient to draw clear conclusions about the research context for chronic pain.


Areas of Research Uncertainty and Study Gaps

Long-term effects are not fully established, particularly when considering outcomes reflecting daily functioning or activity level over months or years. Data for certain groups remain insufficient, and specific findings for certain subgroups are not well established. The available evidence often is limited in evaluating the research context when weighed against other analgesic options.

Key Studies & References Systematic Review on Opioid Treatments for Chronic Pain: Surveillance Report 3

Frequently Asked Questions (FAQ)

Common questions about Fortral (FAQ)

Q: How is Fortral different from traditional full opioid medications?

A: Fortral (pentazocine) is officially classified as a mixed agonist/antagonist pain reliever. This means it affects the body differently than full opioid agonists, such as morphine. According to regulatory documents, pentazocine can actually block the pain-relieving effects of full opioid agonists and may potentially precipitate withdrawal symptoms in patients who are physically dependent on a pure agonist.


Q: What is the typical timeframe for Fortral to start working for pain relief?

A: Official clinical pharmacology information indicates that following oral administration (tablets), the onset of significant pain relief typically occurs between 15 and 30 minutes after taking the dose.


Q: How long does the pain-relieving effect of Fortral usually last?

A: Studies described in regulatory documents show that the duration of pain-relieving action for the oral tablet formulation is usually three hours or longer.


Q: Is Fortral intended for short-term or long-term management of pain?

A: Official prescribing information generally advises that Fortral is intended for short-term pain relief. However, it may be used longer, though official information indicates it should be taken for the shortest time necessary to control pain.


Q: Why do people mention hallucinations or nightmares when discussing Fortral?

A: Regulatory documents note that some patients taking therapeutic doses of pentazocine have experienced acute central nervous system (CNS) effects. These can include visual hallucinations, disorientation, and confusion, which typically clear spontaneously within a few hours.


Q: Are there specific mental or psychological side effects associated with Fortral, such as hallucinations?

A: Yes, regulatory labeling documents commonly reported psychological and mental side effects. These effects include euphoria, sedation, confusion, drowsiness, and, in some cases, hallucinations.


Q: Does Fortral interact with common over-the-counter pain medications like Tylenol or Advil?

A: Pentazocine is frequently included alongside acetaminophen (the active ingredient in Tylenol) in co-formulated prescription products. This co-formulation is officially documented, though caution is generally advised when combining any medications. Specific warnings for NSAIDs (like Advil) are not consistently listed across regulatory documents.


Q: Are there documented risks of developing tolerance to Fortral over time?

A: Official information states that tolerance to the pain-relieving effect of pentazocine has been reported only rarely in patients receiving the oral drug for chronic pain over prolonged periods.


Q: Is Fortral generally considered compatible with breastfeeding, according to official sources?

A: Official safety advice notes that pentazocine passes into breast milk. This may cause harm to the infant. Official advice recommends that infants be observed carefully for signs such as increased sleepiness, difficulty breathing, or limpness.


Q: Is Fortral the same drug substance as the brand name Talwin?

A: Yes, Fortral contains the active ingredient pentazocine, and some combination products are the brand equivalent to a drug previously known as Talwin NX Tablets.


Q: Are there warnings about Fortral affecting sexual function or fertility in men or women?

A: Regulatory documents indicate that the long-term use of opioids, including pentazocine, may disrupt the body's hormonal systems. This can lead to androgen deficiency (low testosterone) which may result in effects like low libido, impotence, or infertility in both men and women.


Q: Can Fortral cause paradoxical effects, such as increased pain sensitivity?

A: Official warnings state that pentazocine may cause or increase allodynia and hyperalgesia. Allodynia is pain caused by a non-painful stimulus, and hyperalgesia is an increased sensitivity to pain. These effects are documented in official safety information.


Q: What is the maximum duration for which Fortral is typically prescribed?

A: Official labeling does not establish a specific maximum duration of therapy. Pentazocine is generally intended for short-term relief, and official information indicates that the medication should be taken for the shortest time necessary to control pain.


Q: How do different formulations of Fortral affect its onset of action?

A: Official clinical pharmacology text confirms that the oral tablet provides significant pain relief onset typically between 15 and 30 minutes. While the injectable form is addressed separately in official documents, its precise onset information is separate from the oral tablet labeling.


Q: What kinds of food or supplements are documented to interact with Fortral?

A: Official drug information explicitly warns patients about potential interactions with the nonprescription supplements St. John’s Wort and tryptophan.


Q: What research evidence supports the use of Fortral for different types of pain?

A: Pentazocine is officially indicated for the relief of moderate to severe pain when other pain medicines did not work well enough or cannot be tolerated.


Q: Does Fortral have a different safety profile when used in the injection form versus oral tablets?

A: While the core drug effects are similar, the injection form carries unique warnings. These include the risk of pain, redness, or sloughing of the skin (tissue damage) at the injection site, which are concerns specific to that route of administration.


Q: Why is constipation a frequent concern mentioned in discussions about Fortral?

A: Regulatory documents address this by noting that pentazocine acts on the gastrointestinal tract to reduce movement and increase tone in the colon. This documented effect can lead to or result in constipation.


Q: What is the significance of the naloxone component in certain Fortral combination products?

A: Official warnings explain that naloxone is an opioid antagonist included in some oral combination products. When taken by mouth, the naloxone has no effect, but it is intended to neutralize the action of the pentazocine if the combination medicine is dissolved and injected. This mechanism is designed to deter misuse.


Q: Does Fortral affect the ability to drive or operate machinery, as stated in regulatory documents?

A: Due to the potential for sedation, dizziness, and euphoria, official patient information carries a warning regarding impaired ability to drive or operate machinery until the effect of the medication is known.


Q: What research has examined the long-term effects of Fortral on the nervous system?

A: Studies referenced in regulatory text indicate that long-term opioid use can disrupt the hypothalamic-pituitary-gonadal axis, potentially leading to hormonal issues. Overall, regulatory documents also indicate that long-term safety data regarding the oral administration of pentazocine are limited.

How should Fortral be stored and disposed of?

How to Store and Dispose of Fortral (Pentazocine)

Official Storage Conditions

Fortral must be kept in the original container, which should remain tightly closed.

Storage Requirement Condition
Temperature Store at controlled room temperature (20 C to 25 C), avoiding excess heat.
Environment Protect from excess moisture; do not store in the bathroom.
Safety Keep out of the sight and reach of children and in a secure place.

Mandated Disposal Procedures

Due to the risks associated with this controlled substance, unused or expired Fortral must be disposed of promptly and securely.

  • The preferred method is using an official drug take-back program.
  • If a take-back program is unavailable, Pentazocine tablets must be immediately flushed down the toilet as specified by regulatory guidance to prevent accidental ingestion.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fortral found in:

A-Z Index: